Publications in collaboration with researchers from Harvard Medical School (2)

2019

  1. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    The Lancet, Vol. 394, Núm. 10214, pp. 2096-2107

  2. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 20, Núm. 6, pp. 781-794